Form 4 for VKTX Viking Therapeutics, Inc.

Accepted 2025-10-28 00:00:00 ET · period of report 2025-10-27 · accession 0001193125-25-254299 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2025-10-28	2025-10-27	VKTX	Lian Brian	Pres, CEO, Dir	A - Grant	$0.00	+70.1K	2.46M	+3%	$0
	2025-10-28	2025-10-28	VKTX	Lian Brian	Pres, CEO, Dir	S - Sale	$35.01	-39.0K	2.42M	-2%	-$1.37M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, par value $0.00001 per share	2025-10-27	A	A	70,084	$0.00	2,458,098	D	—	—	(F1) The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal.
2	Common	Common Stock, par value $0.00001 per share	2025-10-28	S	D	38,989	$35.01	2,419,109	D	—	—	(F2) These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.